Jazz Pharmaceuticals®

INNOVATING TO TRANSFORM THE LIVES OF PATIENTS

BRUCE COZADD, CHAIRMAN AND CEO

JANUARY 11, 2021

39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Sara
JZP-258 Trial Participant

Life-Changing Medicines. Redefining Possibilities.

Forward-Looking Statements
"Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995

This slide deck and the accompanying oral presentation contain forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future operating results and financial condition, including 2020 financial guidance; expectations regarding the company's future revenues, cash flow, growth and revenue diversification; the company's growth strategy, including pipeline expansion plans and corporate development efforts; ongoing, planned and potential product launches and expected or potential product sales; ongoing, planned and potential clinical trials and other product development and regulatory activities; 2021 and future goals and objectives; the timing of the foregoing events and activities; and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: the ultimate duration and severity of the COVID-19 pandemic and resulting global economic, financial and healthcare system disruptions and the current and potential future negative impacts to the company's business operations and financial results; maintaining or increasing sales of and revenue from the company's oxybate products and other key marketed products; effectively launching and commercializing the company's other products and product candidates; the time-consuming and uncertain regulatory approval process, including the risk that the company's planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; protecting and enhancing the company's intellectual property rights; delays or problems in the supply or manufacture of the company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations, legal proceedings and other actions; obtaining and maintaining adequate coverage and reimbursement for the company's products; identifying and acquiring, in-licensing or developing additional products or product candidates, financing those transactions and successfully integrating acquired product candidates, products and businesses; the company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the company's ability to achieve expected future financial performance and results and the uncertainty of future tax and other provisions and estimates; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and future filings and reports by the company. In addition, while the company expects the COVID-19 pandemic to continue to adversely affect its business operations and financial results, the extent of the impact on the company's ability to generate sales of and revenues from its approved products, execute on new product launches, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its ordinary shares, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration and severity of the pandemic, governmental "stay-at-home" orders and travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Ireland and other countries, and the effectiveness of actions taken globally to contain and treat the disease. Moreover, other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this slide deck and the accompanying oral presentation are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

INNOVATE
EXECUTE
TRANSFORM

Jazz Pharmaceuticals

Patient-Centric Innovation Drives our Strategy

Targeting Two Therapeutic Areas With Significant Market Opportunities



Strong Foundation and Momentum

Well Positioned For Sustainable Growth as We Enter 2021

STRONG COMMERCIAL FRANCHISES

#1 — **Treatment for Narcolepsy**
Xyrem and next generation Xywav

2 — **New Oncology Treatments**
Since 2015
Rapidly growing presence in the treatment of hematological and solid tumor cancers

35% — **Adjusted Net Income CAGR**
From 2010–2019

ROBUST AND PRODUCTIVE PIPELINE

5 — **Potential Product Launches**
Across 2020–2021

>25 — **Projects in R&D Portfolio**
Expanded more than 4x since 2015

9 — **Product Approvals and Commercial Launches**
Since 2015

INVESTING TO LEVERAGE GLOBAL PLATFORM

10 — **Licensing/M&A Deals**
Since 2015
Including Zepzelca

>90 — **Markets Supplied Globally**
Operate in or partner to make medicines available

>$713M — **Operating Cash Flow**
YTD[1]

[1] YTD = January 1, 2020 to September 30, 2020.

2020 Execution Drives Long-Term Value

Key Achievements

PIPELINE

Xywav for EDS and Cataplexy in Narcolepsy
FDA approval

JZP-458 for ALL
Initiated BLA submission
Real-Time Oncology Review

JZP-258 for IH
Compelling topline data

Announcing Today
Initiated rolling sNDA submission

TRANSACTIONS

PharmaMar
U.S. and Canadian rights to Zepzelca (lurbinectedin)

SpringWorks
Acquired FAAH inhibitor (JZP-150)

Redx Pharma
Collaboration on two cancer targets Ras/Raf/MAP kinase pathway

COMMERCIAL

Execute up to five key product launches through 2020 and 2021

Launched in 2020
Xywav (EDS and cataplexy in narcolepsy)

Zepzelca (2L SCLC)

Sunosi (EDS in OSA and narcolepsy; EU rolling launch)

Preparing for 2021 U.S. Launches[1]
JZP-458 (ALL)
JZP-258 (IH)

[1] Subject to FDA approval

Robust Financial Performance

Investing in Growth Drivers and Delivering Value

BUILDING A SUSTAINABLE NEUROSCIENCE FRANCHISE



RAPIDLY SCALING OUR ONCOLOGY BUSINESS



[1] 2016 to 2019 audited; [2] G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of November 2, 2020. The company expects that, for the year ended December 31, 2020, reported net revenues will meet the guidance range provided on November 2, 2020. Jazz Pharmaceuticals has not finalized its financial results for the year ended December 31, 2020 and actual results may differ.

Commercial Portfolio of High Value Products

Continuing to Deliver Strong Revenue Growth and Diversification

AIMING FOR FURTHER TOP-LINE GROWTH…



…AND ENHANCED DIVERSIFICATION BY 2022



[1] E=Estimated, G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of November 2, 2020. The company expects that, for the year ended December 31, 2020, reported total revenues will meet the guidance range provided on November 2, 2020. Jazz Pharmaceuticals has not finalized its financial results for the year ended December 31, 2020 and actual results may differ; [2] Subject to FDA approval.

Robust and Productive Pipeline for Sustainable Growth

Targeted Investments Designed to Fuel Growth Through 2025 and Beyond

PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY
Undisclosed targets Neuroscience	**JZP-324** Oxybate extended-release formulation	**JZP-385**[4] Essential tremor (Phase 2b)	**Vyxeos** • AML or HR-MDS >60 yrs (AML18)[5] • AML or HR-MDS >18 yrs (AML19)[5] • Newly diagnosed adults with standard- and HR-AML (AMLSG)[5] • Newly diagnosed <22 yrs with AML (COG)[5]	**JZP-258** Idiopathic hypersomnia
CombiPlex Exploratory activities	**Vyxeos** Low Intensity Dosing for higher risk MDS[3]	**JZP-150**[4] PTSD		**JZP-458** (recombinant *Erwinia* asparaginase) ALL/LBL (pivotal Phase 2/3)
JZP-341 (Long-acting *Erwinia* asparaginase)[2] ALL/other hematological malignancies	**Vyxeos + other approved therapies** • R/R AML or HMA Failure MDS[3] • First-line, fit AML (Phase 1b) • Low Intensity Therapy for first-line, unfit AML (Phase 1b)	**Defitelio** • Prevention of CAR-T associated neurotoxicity		
Recombinant pegaspargase[1] Hematological malignancies		**Vyxeos** • HR-MDS (EMSCO)[5] • Newly diagnosed older adults with HR-AML[4,5]		
Pan-Raf Inhibitor Program Raf & Ras mutant tumors		**Vyxeos + venetoclax** *de novo* or R/R AML[3]		
Undisclosed targets Ras/Raf/MAP kinase pathway[2]				
Exosome targets (NRAS, STAT3 and 3 others)[2] Hematological malignancies/solid tumors				
Defibrotide Exploratory activities				

Neuroscience

Oncology

Demonstrated concept to approval capability

xywav™	Launched November 2020
JZP-458 in ALL	Launch targeted mid-year 2021[6]
JZP-258 in IH	Launch targeted 4Q21[6]

[1] Opt-in opportunity. [2] Partnered collaboration. [3] Jazz & MD Anderson Cancer Center collaboration study. [4] Planned. [5] Cooperative group study.
[6] Subject to FDA approval

Diverse and Experienced Management Team

Expanded Capabilities and Leadership to Drive Next Phase of Growth

2003

Bruce Cozadd
Chairman and CEO

2018

Daniel N. Swisher, Jr.
President and COO

Heidi Manna
SVP and Chief Human Resources Officer

2019

Robert Iannone, MD, MSCE
EVP, R&D

Neena M. Patil
SVP and General Counsel

Finbar Larkin, Ph.D.
SVP, Technical Operations

2020

Samantha Pearce
SVP, Europe and International

Renée Galá
EVP and CFO

John Miller
SVP, Global Product Strategy

Kim Sablich
EVP and General Manager, North America

George Eliades
SVP, Corporate Development and Chief Transformation Officer

Jazz Pharmaceuticals

Delivering Significant Value Through 2025 and Beyond

Disciplined Allocation of Capital in Alignment With Our Strategic Priorities

CAPITAL

$1.9B
Cash[1]

$Billions
Expected cash flow through 2025

Significant
Leverage capacity

DISCIPLINED DEPLOYMENT

PIPELINE EXPANSION
Advancing internal assets
Licensing new assets

EXISTING PRODUCTS
New indications
Geographic expansions

CORPORATE DEVELOPMENT
Product acquisitions
Company acquisitions

SHARE REPURCHASES
Opportunistic to maximize long-term return for shareholders

STRATEGIC PRIORITIES

- Diversified and Growing Base of Revenues
- Differentiated Pipeline to Support Future Growth
- Operational Excellence to Maximize TSR

[1] Represents cash and investments as of September 30, 2020.

NEUROSCIENCE



Jazz Pharmaceuticals®

Harry
Sunosi Patient

Delivering Growth, Value and Durability

Neuroscience

Strong Commercial Execution

#1
Sleep disorder medicine by sales since 2014 (Xyrem)

>50%
of oxybate patients on Xywav by 2023

$1.76-1.8B
2020 Neuroscience net sales guidance[1]

3
On-market products

xywav™

SUNOSI

XYREM (sodium oxybate) oral solution

Poised For Sustainable Growth

- Sleep franchise – enhanced durability with first and only FDA approved lower-sodium oxybate, Xywav[2]
- Sleep disorders – important growth opportunity given the high unmet medical needs
- Strong growth prospects for Sunosi in the U.S. and European markets (focus on narcolepsy, OSA and potential new indications)
- Expansion into new areas of unmet need including treatment of essential tremor and post-traumatic stress disorder (PTSD)
- Investing in pipeline with early in-licensed innovative assets with new MOAs

[1] The company expects that, for the year ended December 31, 2020, reported Neuroscience net revenues will meet the guidance range provided on November 2, 2020. Jazz Pharmaceuticals has not finalized its financial results for the year ended December 31, 2020 and actual results may differ.
[2] Xyrem and Xywav warnings: Central nervous system depression and abuse and misuse. For full details see U.S. prescribing information, summary in appendix

Executing a Successful Xywav Launch

Launched November 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in narcolepsy

SODIUM MATTERS

- Xywav is the only lower-sodium oxybate approved for the treatment of cataplexy or excessive daytime sleepiness (EDS) in narcolepsy
- Unlocking the potential in narcolepsy; educating physicians and patients on the lifelong burden of narcolepsy and high sodium intake
- Goal that the majority of oxybate patients are benefiting from Xywav therapy by 2023

LAUNCH HIGHLIGHTS

- Launch progressing well
- Large majority of Xywav prescriptions are to patients who have previously taken Xyrem
- Majority of oxybate naïve patients being prescribed Xywav
- On track to obtaining broad payer coverage
  - Covered on the Express Scripts National Preferred Formulary for commercial lives on first day of launch

JZP-258 Breaking New Ground in Idiopathic Hypersomnia

Initiated Rolling sNDA Submission in Adults in December 2020 — Target Launch 4Q21[1]

MARKET DYNAMICS[2]

~37,000 diagnosed IH patients in the U.S.
High likelihood of under- and mis-diagnosis

~800 physicians account for ~70% of IH diagnoses[1]

~90% overlap with our current call universe

SYMPTOMS

- **Consumed by sleep**
- **Sleep inertia — difficulty waking**
- **Brain fog**
- **Memory loss**
- **Chronic fatigue**
- **Microsleep**

[1] Subject to FDA approval. [2] Jazz market research

[1] SHA claims data for 60 months to 3Q 2019

Sunosi

Strong Foundation: Ready to Execute the Next Phase of Launch

SUNOSI (solriamfetol) tablets

Maximizing the number of patients benefiting from Sunosi

5 Expansion into larger pool of OSA patients and physicians beyond initial targets

4 Target physicians with OSA patients currently untreated for EDS

3
- Expand into OSA patients currently prescribed agents for EDS
- EU rolling launch

2 Establish beachhead in narcolepsy

1
- ~90% commercial payer coverage
- 98% of prescribers would recommend Sunosi to their peers

6,000 Additional OSA Targets

Expanding DTC to TV

JZP-385 — Initially Focused on Essential Tremor

Phase 2b Study Initiation Planned 1H21

- Most common pathological tremor disorder
- Progressive, irreversible and chronic debilitating disorder
- Profound impact on patients' lives and their activities of daily living
- Patients express feelings of "embarrassment," "shame," and "misery"
- No newly approved pharmacotherapy in over 50 years



	KEY HIGHLIGHTS	GROWTH OPPORTUNITIES
JZP-385 Phase 2 Essential Tremor	• Broadens neuroscience pipeline into movement disorders • Differentiated MOA — selective T-type calcium (Ca_V3) channel modulator • Targeted specifically at tremor oscillation centers	• Limited treatment options • High unmet need for a safe, effective and durable treatment option • Development opportunities beyond Essential Tremor

JZP-150 — Initially Focused on PTSD

Phase 2 Study Initiation Targeted in Late 2021

- PTSD results from exposure to actual or threatened death, serious injury or sexual violence
- PTSD represents a global public health problem that is associated with significant morbidity and mortality
- PTSD affects up to 8% of adults during their lifetime[1]
- No newly approved pharmacotherapy in almost two decades
- Medications with a novel mechanism of action that can address the pathophysiology of PTSD are needed



	KEY HIGHLIGHTS	GROWTH OPPORTUNITIES
FAAHi Phase 2 ready PTSD	• Differentiated MOA (irreversible binding) • Potential to impact pathophysiology and symptoms of PTSD (fear extinction learning, anxiety / depression and sleep architecture) • Demonstrated benefit on fear extinction and stress responses in health volunteers[2]	• U.S. target population ~2M • Limited treatment options • High unmet need for a safe, effective and durable treatment option • Development opportunities beyond PTSD

[1] Kilpatrick, D., Resnick, H., Milanak, M., Miller, M., Keyes, K. and Friedman, M., 2013. National Estimates of Exposure to Traumatic Events and PTSD Prevalence Using DSM-IV and DSM-5 Criteria. *Journal of Traumatic Stress*, 26(5), pp.537–547; [2] Mayo LM, Asratain A., Lindé J et al. Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biol Psychiatry. 2020 Mar 15; 87(6): 538-547

ONCOLOGY

Jazz Pharmaceuticals®

Tim
AML Patient

Rapidly Growing Our Oncology Business

Strong Commercial and Development Capabilities

Revenue Diversification Driver

~$2B
Oncology sales 2015-2019

3
Products contributed $100M+ each in 2019

$525-565M
2020 Oncology net sales guidance[1]

5
Key approvals since 2015

Poised For Meaningful Growth

- Continued double-digit growth in portfolio
- Future revenue growth and diversification fueled by recent Zepzelca launch and planned JZP-458 launch mid-2021
- Expansion into solid tumors with Zepzelca
- Important growth opportunities for JZP-458 through expanded treatment and globalization
- Defitelio and Vyxeos remain important therapies for patients with significant unmet medical needs
- Investing in a deep and broad pipeline of innovative targets

[1] The company expects that, for the year ended December 31, 2020, reported Oncology net revenues will meet the guidance range provided on November 2, 2020. Jazz Pharmaceuticals has not finalized its financial results for the year ended December 31, 2020 and actual results may differ.

Strong Start to Zepzelca Launch

Demonstrating Launch Execution Excellence

ZEPZELCA™ (lurbinectedin)

Launched July 2020 following FDA accelerated approval for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy

LAUNCH HIGHLIGHTS

- Strong initial launch with 3Q revenues of $37M and growth in 4Q
- Similar share of use across platinum resistant and platinum sensitive 2L SCLC patients[1]
- Included in NCCN® Guidelines from launch
- Positive feedback from physicians and increased awareness through education and promotion[2]

STRATEGIC FIT

- Further diversifies commercial portfolio; expands into solid tumors
- Provides meaningful multi-hundred million dollar opportunity with 3–5 year route to peak
- Synergistic with existing portfolio
- SCLC opportunity: Currently ~17,000 patients per year treated; ~8,000 patients do not receive 2L treatment
- Joint development plan with PharmaMar includes:
  - Evaluation of other tumor types
  - 1L SCLC in combination with I/O and other agents

[1] Based on insurance claims data, ~ 3 month lag
[2] Based on Jazz market research

JZP-458: Driven by Patient Need

Demonstrating R&D and Partnering Excellence

INNOVATE
Significant need for reliable, consistent, high quality supply

EXECUTE
Optimal usage; Global expansion; R&D

TRANSFORM
Optimize treatment; Save lives

RAPID PROGRESSION FROM PHASE 1 TO TARGETED LAUNCH IN < 2 YEARS[1]

2016 — Initial discussions with FDA on concept of a recombinant product

2019 — Phase 1 completed

2020 — Real-Time Oncology Review BLA submission initiated December 2020

2021 — OBJECTIVE: launch mid-2021[1]

[1] Subject to FDA approval

EXECUTING FOR VALUE CREATION

Jazz Pharmaceuticals®

Meaghan
Narcolepsy Patient

2021 Goals

Aligned to Patient-Centric Strategy and Key Objectives

PATIENT-CENTRIC INNOVATION DRIVES OUR STRATEGY

Innovate to transform the lives of patients

- Expand our pipeline and diversify revenues through acquisitions, collaborations, and internal initiatives
- Build a high value portfolio of assets through disciplined portfolio management and capital allocation

CONTINUED COMMERCIAL EXECUTION EXCELLENCE

Targeted launches:

- JZP-458: mid-year 2021[1]
- JZP-258 IH: 4Q21[1]

Continue to focus on:

- Rapid U.S. adoption and broad access for Xywav
- Sunosi growth globally
- Driving Zepzelca as the treatment of choice for 2L SCLC patients

ROBUST AND PRODUCTIVE PIPELINE

Key Pipeline Milestones:

- Initiate phase 2b study for JZP-385 in ET in 1H21
- Initiate phase 2 study for JZP-150 in PTSD in late 2021
- Initiate phase 3 study for Zepzelca in combination with I/O in 1L SCLC

2021
5 key launches through 2020 and 2021

2022
Nearly half of revenues from products launched since 2019

2023
Majority of oxybate patients on Xywav

[1] Subject to FDA approval

Delivering Meaningful Shareholder Value

- Patient-Centric Innovation to Drive Our Strategy
- Experienced Leadership Team to Execute on Strategy and Deliver Value
- Strong Financial and Operational Track Record Generating >$2B in Annual Revenue
- High Value Neuroscience and Oncology Products Poised for Continued Growth and Diversification
- Global Commercial Footprint and Operations to Rapidly Advance and Scale Products
- Robust and Productive Development Pipeline Designed for Sustainable Growth
- Strong Balance Sheet and Cash Flow to Enable Strategic and Disciplined Capital Deployment
- Multiple Important Catalysts in 2020-2021 Providing Foundation for Transformative Growth

INNOVATE
EXECUTE
TRANSFORM

Jazz Pharmaceuticals

APPENDIX

Jazz Pharmaceuticals®

Glossary of Terms

1L / 2L / 3L = First / Second / Third Line
ALL = Acute Lymphoblastic Leukemia
AML = Acute Myeloid Leukemia
AMLSG = AML Study Group
BLA = Biologics License Application
CAGR = Compound Annual Growth Rate
CAR-T = Chimeric Antigen Receptor T-cell Therapy
COG = Children's Oncology Group
DTC = Direct-to-Consumer
EDS = Excessive Daytime Sleepiness
EMSCO = European Myelodysplastic Syndromes Cooperative Group
ET = Essential Tremor
FAAH (i) = Fatty Acid Amide Hydrolase (Irreversible)
FDA = U.S. Food and Drug Administration
HMA = Hypomethylating Agent
HR-AML = High-Risk AML
HR-MDS = High-Risk MDS
IH = Idiopathic Hypersomnia
IND = Investigational New Drug Application
LBL = Lymphoblastic Lymphoma
M&A = Mergers & Acquisitions
MAP = Mitogen-activated Protein
MDACC = MD Anderson Cancer Center
MDS = Myelodysplastic Syndrome
MOA = Mechanism of Action
NCCN = National Comprehensive Cancer Network
OSA = Obstructive Sleep Apnea
PharmaMar = Pharma Mar, S.A.
PTSD = Post-Traumatic Stress Disorder
R&D = Research & Development
R/R = Relapsed / Refractory
SCLC = Small Cell Lung Cancer
SHA = Symphony Health
sNDA = Supplemental New Drug Application
SpringWorks = SpringWorks Therapeutics, Inc.
TSR = Total Shareholder Returns
TTCC = T-Type Calcium Channel

Warnings

XYREM

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.

• Central Nervous System Depression

Xyrem (sodium oxybate) is a CNS depressant. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated with Xyrem [see Warnings and Precautions (5.1)]. Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials (14)].

• Abuse and Misuse

Xyrem® (sodium oxybate) is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions (5.2)].

Because of the risks of CNS depression and abuse and misuse, Xyrem is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS [see Warnings and Precautions (5.3)].

VYXEOS

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

• VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors [see Warnings and Precautions (5.1)].

XYWAV

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.

• Central Nervous System Depression

XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses [see Warnings and Precautions (5.1, 5.4)]. Many patients who received XYWAV during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials (14.1)].

• Abuse and Misuse

The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions (5.2)].

Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS [see Warnings and Precautions (5.3)].